OpenNashEarnings

HCA Healthcare (HCA) · Health Care

HCA Healthcare Q3 2026 earnings call: transcript, summary & key numbers

Results filed 27 Oct 2026 · Quarter ended 30 Sep 2026 · Call 60 min · Sam Hazen (CEO), Mike Marks (CFO)

Read the transcriptPress release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

HCA grew volumes for a 22nd straight quarter on emergency, neonatal and ambulatory demand, even as lost exchange coverage pushed more patients into uninsured status.

HCA's patient volumes kept growing, led by emergency room visits, neonatal, cardiac and trauma care, while elective surgery stayed weak. Many patients who lost health insurance exchange coverage became uninsured almost one-for-one, and uninsured patients reached about 10.5 % of equivalent admissions. Insured demand grew faster than in the first half of the year. Hospitals are running at record occupancy, and management is adding beds and expanding its outpatient network.

Management's early view of 2027 is for volume growth of 2 to 3% and earnings roughly in line with 2026, with the guidance coming in January. It is betting on its enterprise-wide cost program, digital transformation and ambulatory network development. The main tension is policy: exchange enrollment, Medicaid work requirements and fewer one-time supplemental payments could still erode payer mix before the underlying growth shows through.

Key numbers

Revenues · GAAP
$19.849 billion

up 3.6% from a year ago

Net income attributable to HCA Healthcare, Inc. · GAAP
$1.579 billion

down 3.9% from a year ago

Diluted EPS · GAAP
$7.27

up 4.5% from a year ago

Diluted EPS, as adjusted · non-GAAP
$7.22

up 3.7% from a year ago

Cash flows from operating activities · GAAP
$4.461 billion

compared to $4.416 billion a year ago

Adjusted EBITDA · non-GAAP
$3.918 billion

up 1.2% from a year ago

Segment or metricValueChange
Same facility admissions2.7 percentincrease vs. prior year
Same facility equivalent admissions3.0 percentincrease vs. prior year
Same facility emergency room visits5.1 percentincrease vs. prior year
Same facility inpatient surgeries1.4 percentdecline vs. prior year
Same facility outpatient surgeries3.7 percentdecline vs. prior year
Same facility revenue per equivalent admission0.6 percentincrease vs. prior year
Hospitals operated189 hospitals
Ambulatory sites of careapproximately 2,600
Where each number comes from
  • Revenues: “Revenues in the third quarter of 2026 totaled $19.849 billion, compared to $19.161 billion in the third quarter of 2025.”
  • Net income attributable to HCA Healthcare, Inc.: “Net income attributable to HCA Healthcare, Inc. totaled $1.579 billion, or $7.27 per diluted share, compared to $1.643 billion, or $6.96 per diluted share, in the third quarter of 2025.”
  • Diluted EPS: “Net income attributable to HCA Healthcare, Inc. totaled $1.579 billion, or $7.27 per diluted share, compared to $1.643 billion, or $6.96 per diluted share, in the third quarter of 2025.”
  • Diluted EPS, as adjusted: “and diluted earnings per share, as adjusted, increased 3.7 percent to $7.22 per diluted share”
  • Cash flows from operating activities: “Cash flows from operating activities totaled $4.461 billion, compared to $4.416 billion in the third quarter of 2025”
  • Adjusted EBITDA: “For the third quarter of 2026, Adjusted EBITDA totaled $3.918 billion, compared to $3.870 billion in the third quarter of 2025.”
  • Same facility admissions: “Same facility admissions increased 2.7 percent and same facility equivalent admissions increased 3.0 percent in the third quarter of 2026, compared to the prior year period.”
  • Same facility equivalent admissions: “Same facility admissions increased 2.7 percent and same facility equivalent admissions increased 3.0 percent in the third quarter of 2026, compared to the prior year period.”
  • Same facility emergency room visits: “Same facility emergency room visits increased 5.1 percent in the third quarter of 2026, compared to the prior year period.”
  • Same facility inpatient surgeries: “Same facility inpatient surgeries declined 1.4 percent, and same facility 1 outpatient surgeries declined 3.7 percent in the third quarter of 2026”
  • Same facility outpatient surgeries: “Same facility inpatient surgeries declined 1.4 percent, and same facility 1 outpatient surgeries declined 3.7 percent in the third quarter of 2026”
  • Same facility revenue per equivalent admission: “Same facility revenue per equivalent admission increased 0.6 percent in the third quarter of 2026, compared to the third quarter of 2025.”
  • Hospitals operated: “As of September 30, 2026, HCA operated 189 hospitals and approximately 2,600 ambulatory sites of care”
  • Ambulatory sites of care: “As of September 30, 2026, HCA operated 189 hospitals and approximately 2,600 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ3 2026vs year agovs last quarter
Revenue$19.8B+3.6%−1.9%
Net income$1.6B−3.9%−7.1%
Diluted EPS$7.27+4.5%−4.6%
Free cash flow$3.1B−0.8%+181.2%

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Revenuesyear ending December 31, 2026$77,000 | $79,500
Net income attributable to HCA Healthcare, Inc.year ending December 31, 2026$6,300 | $6,700
Adjusted EBITDAyear ending December 31, 2026$15,400 | $16,100
Diluted EPSyear ending December 31, 2026$28.70 | $30.50
Incremental net benefit from Medicaid supplemental payment programsfull year 2026between $600 million and 800 million
Same facility volume growth20272 to 3%
Reduction in Medicaid supplemental payment net benefits vs. 20262027$550 million to $650 million

Key takeaways

  1. Exchange coverage losses are reshaping HCA's payer mix

    Patients who lost exchange coverage migrated almost one-for-one to uninsured, lifting uninsured to approximately 10.5 % of equivalent admissions from 8.5 % a year earlier, while exchange equivalent admissions fell approximately 19 %. Management expects a meaningful payer-mix effect again in 2027, though with fewer people losing coverage.

  2. Emergency and acute services offset weak elective surgery

    ER visits rose 5.1% while outpatient surgeries fell 3.7%, and management says neonatal, cardiac, trauma and EMS volumes are strong. It attributes elective softness mainly to coverage loss, with general affordability second.

  3. Ambulatory expansion and added capacity are driving growth

    HCA now has almost 3,000 ambulatory units and is adding beds while running occupancy near 75 %. Patient-flow initiatives and a reorganized ambulatory platform are meant to feed patients into its hospital system.

  4. Resiliency program is becoming a permanent operating model

    Management describes four focus areas: revenue integrity, asset optimization, variable costs and fixed costs. Digital transformation and expanded shared services at Paralon are cited as enablers for 2027 and 2028.

  5. Early 2027 view: steady earnings, 2 to 3% volume growth

    Management expects 2027 earnings generally consistent with 2026, with volume growth offset by lower Medicaid supplemental payments. A proposed Medicare outpatient rule on 340B would benefit HCA, but it is not sized yet.

Charts

Revenue$19.8B+3.6% y/yQ3 2026
Q4 2024: $18.3B (worked out from the annual figure)Q4 ’24$18.3BQ1 2025: $18.3BQ1 ’25$18.3BQ2 2025: $18.6BQ2 ’25$18.6BQ3 2025: $19.2BQ3 ’25$19.2BQ4 2025: $19.5B (worked out from the annual figure)Q4 ’25$19.5BQ1 2026: $19.1BQ1 ’26$19.1BQ2 2026: $20.2BQ2 ’26$20.2BQ3 2026: $19.8BQ3 ’26$19.8B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$18.3B *
Q1 2025$18.3B
Q2 2025$18.6B
Q3 2025$19.2B
Q4 2025$19.5B *
Q1 2026$19.1B
Q2 2026$20.2B
Q3 2026$19.8B
Diluted EPS (GAAP)$7.27+4.5% y/yQ3 2026
Q1 2025: $6.45Q1 ’25$6.45Q2 2025: $6.83Q2 ’25$6.83Q3 2025: $6.96Q3 ’25$6.96Q1 2026: $7.15Q1 ’26$7.15Q2 2026: $7.62Q2 ’26$7.62Q3 2026: $7.27Q3 ’26$7.27
Data
Q1 2025$6.45
Q2 2025$6.83
Q3 2025$6.96
Q1 2026$7.15
Q2 2026$7.62
Q3 2026$7.27

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Free cash flow$3.1B−0.8% y/yQ3 2026
Q4 2024: $1.3BQ4 ’24$1.3BQ1 2025: $660.0MQ1 ’25$660.0MQ2 2025: $3.0BQ2 ’25$3.0BQ3 2025: $3.1BQ3 ’25$3.1BQ4 2025: $870.0MQ4 ’25$870.0MQ1 2026: $895.0MQ1 ’26$895.0MQ2 2026: $1.1BQ2 ’26$1.1BQ3 2026: $3.1BQ3 ’26$3.1B
Data
Q4 2024$1.3B
Q1 2025$660.0M
Q2 2025$3.0B
Q3 2025$3.1B
Q4 2025$870.0M
Q1 2026$895.0M
Q2 2026$1.1B
Q3 2026$3.1B

Operating cash flow minus capital expenditure, from cash flow statements.

What management said

Each quote matches the transcript word for word.

“We're up to almost 3,000 units through acquisition of urgent care, ambulatory surgery centers, and other outpatient facilities that complement our hospital's ecosystem and create for our patients a more convenient and accessible location and efficient service.”

It shows the scale of the ambulatory network HCA is building around its hospitals.

0:42:51 · Sam Hazen (CEO)

“We're running the company at an all-time high when it comes to occupancy levels, pushing 75 % on our inpatient platform.”

It signals capacity strain and explains why HCA is adding beds and improving patient flow.

0:44:26 · Sam Hazen (CEO)

“We're seeing more growth in other services that are compensating for some of the surgical growth or surgical declines that we're experiencing.”

It shows HCA's service diversity cushioning weak elective surgery.

0:18:38 · Sam Hazen (CEO)

“Coverage for people matters. And it creates access, affordability, and elective care.”

Management ties elective surgery weakness directly to lost exchange coverage.

0:31:59 · Sam Hazen (CEO)

“When we think about resiliency, you know, we largely think about four key focus areas that really make up this multi-faceted effort across the enterprise.”

It frames the cost and operations program as a structured, multi-year strategy.

0:56:42 · Mike Marks (CFO)

“HCA and many of the major payers are working diligently to eliminate the friction, create a more cost-effective solution, and sort of reduce the administrative complexity that exists within the system.”

It points to a possible shift in how HCA works with insurers beyond contract negotiations.

0:48:27 · Sam Hazen (CEO)

Analyst Q&A

  1. 0:11:31 · AJ Rice, UBS · 2027 outlook

    Can management size the 2027 exchange headwind and say whether resiliency savings will resemble this year's program?

    Management said it will give detail on the January call after seeing fourth-quarter results and exchange enrollment, and that resiliency is an ongoing strategic program with more value expected in 2027. — Mike Marks, Sam Hazen

  2. 0:15:27 · Ann Hines, Mizuho · 340B

    Does the flat 2027 outlook assume any change or benefit from the proposed 340B regulation?

    The proposed budget-neutral 340B reallocation in the Medicare outpatient rule would benefit HCA, but management is not sizing it publicly yet. — Mike Marks

  3. 0:16:41 · Ben Hendricks, RBC Capital Markets · Surgical volumes

    How does the surgical backdrop and any pent-up demand fit into the 2 to 3% volume outlook for next year?

    Management has not landed on surgical assumptions, noting emergent, neonatal, cardiac and trauma strength offsetting weak elective care driven mainly by coverage and affordability. — Sam Hazen

  4. 0:19:14 · Brian Tankulit, Jefferies · Labor and costs

    What explains the sequential moves in salaries and benefits and other operating expenses, and what is happening with temporary staffing?

    Salaries rise seasonally in the third quarter from merit adjustments, cost per equivalent admission was flat year over year, and professional fees rose about 12 % driven by radiology and anesthesiology. — Mike Marks

  5. 0:21:38 · Peto Chikering, Deutsche Bank · Core growth

    Is 2027 adjusted core EBITDA growth still in a 4 % to 6 % range, and how much does resiliency contribute?

    Management treats resiliency as part of core operations, said third-quarter core growth was about 10 %, and deferred 2027 detail to the fourth-quarter call. — Mike Marks

  6. 0:23:43 · Matthew Gilmer, KeyBanc · Pricing

    What drove the acceleration in insured revenue per equivalent admission?

    Strong commercial volume excluding exchanges, solid rate growth across payer categories, and improved collections and underpayment recovery at Paralon. — Mike Marks

  7. 0:25:14 · Sam Dodge, BMO Capital Markets · Q4 guidance

    What gives visibility that fourth-quarter core growth will accelerate under upper-half guidance?

    Management said it implies core growth fairly consistent with the third quarter, supported by volume strength, normal seasonal revenue-per-unit step-up and resiliency cost benefits. — Mike Marks

  8. 0:27:05 · Witt Mayo, Lee Rink · Exchange headwind

    Did the exchange headwind grow in a particular market, and did it affect collectability?

    Exchange volumes fell about 19 % versus an expected 15 to 16 %, reflecting a tough prior-year comparison and sustained declines, though they improved about 8 % sequentially. — Mike Marks

  9. 0:28:58 · Ryan Langston, TD Cowen · ASC volumes

    How did ambulatory surgery center versus hospital outpatient surgical volumes perform?

    ASC surgery volumes fell 5.4 % and hospital-based outpatient surgeries fell 2.9 %, mainly from exchange pressure, though ASC revenue and earnings still grew. — Sam Hazen

  10. 0:30:41 · Sarah James, Cantor Fitzgerald · Elective affordability

    How much surgical pressure is exchange-related versus affordability, and is a deductible-reset pull-forward assumed in the fourth quarter?

    Exchange coverage loss explains a very large share of elective weakness, and the fourth quarter assumes only normal seasonality with no pull-forward. — Sam Hazen

  11. 0:32:44 · Justin Lake, Wolfe Research · Supplemental payments

    How much of the 2027 supplemental payment decline is out-of-period items, and how much sequential exchange growth is assumed for the fourth quarter?

    The decline stems mainly from out-of-period grandfather approvals, chiefly Florida, and management declined to quote a Q3-to-Q4 exchange move while noting an easier comparison. — Mike Marks

  12. 0:35:19 · Kevin Fishbeck, Bank of America · Guidance walk

    Is the guidance increase mostly more supplemental payments offset by higher payer-mix headwinds, and does the exchange headwind include lost surgery?

    Supplemental benefit rose about $300 million and the exchange headwind by $100 to $200 million, with core growth also contributing to the upper-half guidance. — Mike Marks

  13. 0:37:17 · Scott Fidel, Goldman Sachs · Medicaid policy

    What is the fourth-quarter elective outlook, and how might the 1115 waiver budget-neutrality policy affect 2027?

    No elective pickup is assumed in the fourth quarter, and Medicaid work requirements would touch roughly 15 % to 20 % of Medicaid volume with a modest 2027 impact. — Mike Marks

  14. 0:40:29 · Stephen Baxter, Wells Fargo · Payer volumes

    What was year-over-year adjusted admissions growth by payer class?

    Medicare rose 3.2 %, Medicaid 2.7 %, commercial excluding exchanges 2.7 %, and exchanges fell 19 %. — Mike Marks

  15. 0:40:56 · Jason Casorla, Guggenheim Securities · Volume drivers

    What is driving the volume strength, and how do market initiatives fit into 2 to 3% growth next year?

    Inherent market demand, share gains, ambulatory network growth, patient coordination, added capacity and physician support all contribute, and no single factor can be isolated. — Sam Hazen

  16. 0:46:20 · Raj Kumar, Stevens · Payer contracting

    Are payers building explicit coding assumptions into 2028 contracts, and how widespread is that?

    Management did not address coding directly, saying 2027 contracting is well advanced, 2028 is progressing, and it is working with payers to reduce administrative friction. — Sam Hazen

  17. 0:49:07 · Benjamin Rossi, J.P. Morgan · Portfolio

    Is HCA considering market exits or acting as a buyer given industry pressures?

    It sees no significant change to its 43-market footprint after pruning, and would be opportunistic on new markets if affordable. — Sam Hazen

  18. 0:52:06 · Andrew Mock, Barclays · Inpatient-only list

    How is removal of the inpatient-only list affecting procedure migration and capacity plans?

    Year one is hitting orthopedic and musculoskeletal inpatient cases, but it will not materially change network build-out, and service diversity helps offset it. — Mike Marks, Sam Hazen

  19. 0:56:03 · Craig Huttenbach, Morgan Stanley · Resiliency

    Which resiliency applications are accelerating, and what opportunities remain longer term?

    Four areas drive it: revenue integrity, asset optimization, variable costs and fixed costs, enabled by digital transformation and expanding shared services. — Mike Marks

Questions

What is driving HCA's volume growth?

Management cites underlying demand from population growth and aging, incremental market share gains, a growing ambulatory network of almost 3,000 units, added beds and capacity, patient flow initiatives and physician support. It was the 22nd consecutive quarter of volume growth.

How are health insurance exchange coverage losses affecting HCA?

Patients who lost exchange coverage migrated almost one-for-one to uninsured, taking uninsured to about 10.5 % of equivalent admissions from 8.5 %. HCA estimates the payer-mix shift cut adjusted EBITDA by about 400 million in the quarter.

Why is elective surgery weak while other services grow?

Management says coverage loss on the exchanges is the primary force on elective care, with affordability second. Emergency, neonatal, cardiac, trauma and EMS volumes remain strong and compensate.

What is HCA's preliminary outlook for 2027?

It expects volume growth of 2 to 3% and earnings generally consistent with 2026, with fewer exchange coverage losses but $550 million to $650 million less in Medicaid supplemental benefits. Full guidance comes in January.

What is HCA's resiliency program and why does it matter?

It is an enterprise-wide effort covering revenue integrity, asset optimization, variable costs and fixed costs, aided by digital transformation and shared services at Paralon. Management now treats it as an ongoing strategic program supporting 2027, 2028 and beyond.

Documents

From HCA Healthcare investor relations

SEC filing

Transcript

Call recording on YouTube ↗. Official replay ↗. Timestamps jump to the moment.

0:00:00
Operator

Welcome to the HCA Healthcare Third Quarter 2026 Earnings Conference Call. Today's call is being recorded. After today's prepared remarks, we will host a question and answer session. We kindly ask that you please limit yourself to one question. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. At this time for opening remarks and introductions, I would like to turn the call over to Vice President of Investor Relations, Mr.

0:00:33

Frank Morgan. Frank, please go ahead, sir.

0:00:35
Frank Morgan (Investor Relations)

Good morning, and welcome to everyone on today's call. With me this morning is our CEO, Sam Hazen, and our CFO, Mike Marks. Sam and Mike will provide some prepared remarks, and then we'll take your questions. Before I turn the call over to Sam, let me remind everyone that should today's call contain any forward-looking statements, they're based on management's current expectations. Numerous risks, uncertainties, and other factors may cause actual results to differ materially from those that might be expressed today.

0:01:05

More information on forward-looking statements and these factors are listed in today's press release and in our various SEC filings. On this morning's call, we may reference measures such as adjusted EBITDA, which is a non-GAAP financial measure, a table providing supplemental information on adjusted EBITDA and reconciling net income attributable to HCA Healthcare Dean is included in today's release. This morning's call is being reported and a replay of the call will be available later today. With that, I'll now turn the call over to Sam.

0:01:38
Sam Hazen (CEO)

Good morning, and thank you for joining the call. The company's results in the third quarter reflected improvement in key areas of our business. First, demand for our services continued to grow at a solid rate. Adjusted admissions on a same facility basis grew 3 % compared to 2.3 % year-to-date. Inside this growth, insured volumes grew faster in the quarter than in the first half of the year. The third quarter reflected the 22nd consecutive quarter of volume growth for the company.

0:02:14

Second, revenue per adjusted admission for our insured business, excluding supplemental payments increased at a higher rate than in the first half of the year. This increase partially offset the payer mix pressure from continued volume declines for patients who were formerly covered in health insurance exchanges and are now uninsured. Additionally, we had a modest incremental net benefit of $50 million in the quarter from Medicaid supplemental payment programs, primarily related to a recently approved Virginia program. These factors, coupled with improved cost results, contributed to solid financial performance in the quarter that slightly exceeded our expectations.

0:03:02

Diluted earnings per share, as adjusted, increased almost 4%. I have often mentioned that HCA has strong staying power because of our scale, the important role we play in providing critical services to communities, and our disciplined culture. Despite the challenges this year brought about by federal policy changes, we have continued to move the company forward and believe we are positioned to end the year positively. belief. As we look ahead to 2027, let me share a few preliminary observations around certain aspects of our business before we provide our full year guidance in January.

0:03:47

I'll remind everyone we are still early in our planning process and there are several important areas that remain fluid, including the policy environment. First, we expect demand for services to remain strong with volume growth forecasted to be 2 to 3%. This range is consistent with our long-term thinking. Within the demand environment, we believe it's reasonable to assume for 2027 that fewer people will lose their coverage on the health insurance exchanges than we experienced in 2026.

0:04:23

However, we do expect that there still will be a meaningful impact on payer mix. We need to get through the fourth quarter before we can provide more details. Next, we expect to receive approximately $550 million to $650 million less in Medicaid supplemental payment net benefits due to various state programs that received grandfather approvals in 2026 and reimbursed us for services we provided in prior years. Last, we anticipate favorable cost performance, primarily due to our ongoing enterprise-wide resiliency program and the operating leverage from the expected volume growth.

0:05:08

When we aggregate these preliminary observations, we anticipate our earnings in 2027 will be generally consistent with 2026. Beyond 2027, we anticipate performance more in line with our long-term growth targets. This view makes three important assumptions. First, we move past the most significant effects on payer mix from the exchanges. Second, we assume no material policy changes beyond HR1. And finally, we have a set of strategic initiatives, including digital transformation, network development and ongoing resiliency programs that generate significant value.

0:05:52

I'll reiterate it is still early but we believe these preliminary perspectives provide context for how we currently see the company's growth prospects. Let me close with this. Our colleagues continue to provide high quality care to our patients and execute our strategic plans. I appreciate their efforts in delivering on our mission and I want to thank them for their good work. As we get further into the execution of our plan, we believe it will enhance access for our patients with our capital spending, create a better work environment for our caregivers with our AI transformation initiatives, and deliver value for our shareholders with our enterprise-wide resiliency program and balanced capital allocation.

0:06:40

As we look to the future, I'm confident that HCA Healthcare has the right people, the right process, and the financial position to achieve our long-term objectives. With that, I'll turn the call over to Mike for more details on the quarter.

0:06:56
Mike Marks (CFO)

Thank you, Sam, and good morning, everyone. As Sam noted, demand for our services continued to grow at a solid rate. Compared to the prior year quarter, on the same facility basis, admissions increased 2.7%. Equivalent admissions increased 3%.

0:07:12

And ER visits increased 5.1%. Inpatient surgeries were down 1.4%. Outpatient surgeries were down 3.7%. Regarding surgical volumes, consistent with the second quarter, we continue to see solid growth in our emergent surgical volumes and pressure collected. Same facility equivalent admissions in our insured population, excluding exchanges, increased approximately 3 % in the third quarter versus prior year. Exchange equivalent admissions declined approximately 19 % versus prior year quarter. For context, the third quarter of 2025 was our high watermark for exchange volume, making for a difficult comparison.

0:07:56

However, we did see sequential improvement in exchange volume from 2Q to 3Q of 2026 of approximately 8%. Like the second quarter, we continue to see patients who have lost coverage on the exchanges migrate almost one-for-one to uninsured. This one-for-one migration makes up approximately 80 % of our uninsured volume growth, with the remaining 20 % primarily related to a decrease in Medicaid conversions. and mostly in Texas. Our uninsured volume in third quarter 26 represented approximately 10.5 % of total equivalent admission versus 8.5 % in the prior year quarter.

0:08:39

We estimate the payer mix shift from exchanges to insured resulted in an unfavorable impact on adjusted EBITDA of approximately 400 million in a quarter. We now expect the full year unfavorable impact on adjusted EBITDA from payer makeshifts to be at or slightly above the upper end of the range of our previously updated estimates. For Medicaid supplemental payment programs, the company recognized approximately $50 million of incremental net benefit during the third quarter. We now expect the incremental net benefit from Medicaid supplemental payment programs to be between $600 million and 800 million for the full year 2026.

0:09:22

this increase in our estimated range was driven equally by the grandfathered application from virginia and one-time payments from across our other programs we were pleased with our cost results in the quarter same facility cost for equivalent admission when excluding medicaid supplemental payment programs was essentially flat versus prior year quarter and it improved 40 basis points sequentially as we typically see an increase sequentially from second quarter to third quarter this outcome reflects strong operating discipline from our teams moving to capital allocation cash flow capital expenditures totaled approximately 1.36 billion in a quarter additionally we purchased approximately $3 billion of our outstanding shares and we paid 165 million dividends for the quarter cash flow from operations was approximately 4

0:10:16

.5 billion in the quarter our debt to adjusted evita leverage remains in the lower half our stated target range and we believe our balance sheet remains strong and well positioned for the future we currently expect to complete most of the existing authorized share repurchase program by year in subject to market conditions and other factors as noted in our release we are reaffirming our estimated guidance ranges for 2026 given our third quarter performance we currently expect to be the upper half of our guidance ranges for the year i will now hand a call back to frank morgan for questions

0:10:54
Frank Morgan (Investor Relations)

thank you mike as a reminder please limit yourself to one question so we might give as many as possible in the

0:11:03

queue an opportunity to ask a question. Christine, you may now give instructions to those who would like to ask a question.

0:11:10
Operator

We will now begin the question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device.

0:11:31

Please stand by while we compile the Q &A roster. Your first question comes from the line of AJ Rice with UBS. AJ, your line is now open.

0:11:44
AJ Rice (UBS)

Thanks. Hi, everybody. Maybe just to, I know it's early to be given a lot of comments about 2027, and you're thinking about consistent EBITDA versus this year. It sounds like you're thinking there is a fairly substantial incremental public exchange headwind that you've got to overcome, and you're also talking about incremental savings from ongoing resiliency programs.

0:12:09

I wonder if there's any way to flesh out sort of an order of magnitude of what you think that incremental public exchange headwind might be next year, even if it's a wide range and similarly so should we look for cost savings similar to the 400 million resiliency program you announced this year next year

0:12:30
Mike Marks (CFO)

well aj i think what we try to do in preparing our early look comments is give you the best information we have at this point as sam noted in his prepared comments we still are in the early stages of our planning cycle and as we kind of finish fourth quarter we're really studying two key components number one is our results in fourth quarter and how the

0:12:56

strength of our core performance continues to mature i think it's clear in third quarter we were pleased with our core growth and we feel like we have momentum we need to validate that in fourth quarter and that'll give us a really good sense of our core growth as we kind of step into 2027 the second thing that we've got to study is the exchange environment and as we go through the fourth quarter first we'll have a better information about how our exchange volumes perform here in the last quarter of the year but we'll also have better intelligence about enrollment and the enrollment period starts on November 1st and it goes through you know mid-January and so with With those

0:13:38

two things, we'll be in a much better position to give you our best sense of this on our January call, our fourth quarter call for 27 guidance. But I think as you think about court growth, you think about the headwinds that we have disclosed related to Medicaid state supplemental payment programs, and then what ends up happening with the exchanges in 27. Those are the big moving parts, and we'll give you further guidance as we get on our fourth quarter call.

0:14:08
Sam Hazen (CEO)

On the cost side, AJ, let me add to the cost. I mean, we see our resiliency agenda broadly as an ongoing strategic program for the company. We now have new capabilities. We have new technology. We're expanding our shared service platform as a result of that, and we're able to move the cost agenda systematically as a company today. And heretofore, we didn't have that ability because we didn't have the capabilities nor the technology and I think the mindset to accomplish it as a result of that.

0:14:44

So when we start thinking about costs in 27, as I mentioned in my comments, we do anticipate more value coming from our resiliency program broadly within our networks and from a cost standpoint overall for the company. And so that is more of a strategic agenda item that will carry itself into the future and be a part of our programmatic efforts as we move beyond 2027. I think the other point, Mike, is the Medicaid Supplemental Payment Program is related to some payments from prior year as we think about 2027 also.

0:15:27
Operator

Our next question comes from the line of Ann Hines with Mizuho. Ann, your line is now open.

0:15:33
Ann Hines (Mizuho)

Great. Thank you so much. I just want to ask about 340B. I know there's a regulation out there that if it goes into effect as is, should benefit the for-profits that don't participate in that program. And I know that would probably be challenged at some point in the legal system, but does that flat guidance assume, you know, any change in that program or any potential benefit?

0:15:58

And if it does, have you sized that? Thanks.

0:16:01
Mike Marks (CFO)

Thanks, Ann. So this is part of the Medicare OPTS rule that's proposed at this point. We were pleased with the construct that is a part of the proposed rule as it relates to a budget neutral reallocation on 340b it would benefit us we have not we're not sizing that publicly at this point uh and you know as we think about kind of our early look statements keep in mind the the idea of being generally consistent is where we are standing here at third quarter we'll give you you know much more detailed information as we get on our fourth quarter call but i would say i mean we view the the opps

0:16:41

rule as proposed and we're hoping that it gets finalized here soon is a positive factor for ACA as we head into 2017.

0:16:50
Operator

Our next question comes from the line of Ben Hendricks with RBC Capital Markets. Ben, your line is now open.

0:16:58
Ben Hendricks (RBC Capital Markets)

Great, thank you very much and I appreciate the demand comments for next year and the expectation for two to 3% volume growth. I'm wondering how the surgical backdrop is fitting into your thoughts there I know you had said that you didn't expect any recovery of the kind of weaker elective trend through the end of this year but as we think about next year is there pending demand getting pinned up there that that they could unwind and would

0:17:29

would that be upside to that two to 3% or would that be considered in there any thoughts on how you're thinking about surgical progression for next year thanks

0:17:41
Sam Hazen (CEO)

Ben, we haven't landed on components of that growth just yet. We have, you know, some viewpoints. I think, again, we need to get through the fourth quarter, see how the seasonality on surgery plays out in the fourth quarter. I think, you know, our emergent business, as Mike spoke to, continues to be strong.

0:18:03

We see some macro forces impacting the elective business, coverage being the primary macro force, and then just sort of general affordability across the economy being a second one. So I think from that standpoint, we haven't landed on any surgical viewpoints. But I think it's important for everyone to understand that our composition of volume is fairly diverse. I mean, we have cardiac, we have women's, we have NICU, we have transplant programs, we have surgery, yes, medicine, critical care.

0:18:38

All of these components are attributes of our company that we think give us an ability to navigate through a component not being as productive as we want. And that's what we're seeing. We're seeing more growth in other services that are compensating for some of the surgical growth or surgical declines that we're experiencing. For example, our neonatal activity in the quarter was very strong. Our cardiac business continues to be strong. Our trauma business, strong. EMS traffic to our hospitals, up significantly.

0:19:14

So there's all of these elements that go into our volume assumption. We're not ready to sit there and call out surgery specifically for 2027 until we get a better viewpoint of it through the seasonality patterns that typically exist in the fourth quarter.

0:19:31
Operator

Your next question comes from the line of Brian Tankulit with Jefferies. Brian, your line is now open.

0:19:38
Brian Tankulit (Jefferies)

Hey, good morning, guys. Maybe, Mike, as I look at the SWB and the operating expense lines SWV up sequentially other OPEX down anything you can call out there especially as we think through TEP staffing we're seeing indicators that it looks like TEP nurse staff orders are picking up so just curious what you can share with us on those two line

0:20:03

items especially given resiliency efforts thanks

0:20:05
Mike Marks (CFO)

sure and I mean that's part of this answers is consistent with our sequential notes that we had in my prepared comments, Brian. You know, typically when we go from second quarter to third quarter, that is the timing of when we do a lot of our merit adjustments in labor. And so we typically see, you know, even a hundred basis point increase in our expense for AA overall. And that's one of the factors.

0:20:31

And so we were actually really pleased when we looked at our expenses per equivalent emissions, you know, obviously excluding state supplemental payments. you know one they were essentially flat to prior year but two they were 40 basis points sequentially down uh you know from second quarter to third quarter which you know we think really reflects the the strength of not only our resiliency plan but also the operating leverage we're getting from states of most payments i mean if you look at swb on a margin basis to prior year even with you know the softer overall revenue we had a 40 basis point margin so we were uh we were pleased with that.

0:21:11

And same thing, you know, we had good performance in supplies as well. You know, in other operating expenses, you know, if you just look at third quarter to prior year, you do have a bit of cost related to the state supplemental payments. Keep that in mind. Professional fees continue to be a pressure point for the company. We were up about 12 % versus prior year quarter. and professional fees now represent about 24 % of other operating expenses.

0:21:38

And I would note that those, you know, continue to be driven by radiology and anesthesiology. So that's a, Brian, that's a bit of a rundown on the call side.

0:21:49
Operator

Your next question comes to the line of Peto Chikering with Deutsche Bank. Peto, your line is now open.

0:21:56
Peto Chikering (Deutsche Bank)

Hey, good morning, guys. It takes me to take my question. I'm going to ask AJ's question a little differently. You know, you quantified the $600 million, you know, or $550, $650 of Medicaid for loan payments.

0:22:09

You talked qualitatively about the Medicaid impact next year and the, you know, core mission growth of 2 % to 3%. Can you confirm that 2027 adjusted core EBITDA growth is still in a 4 % to 6 % range? The other piece is impacting that, or is core running hotter or lower? How much is resiliency driving that core growth?

0:22:31
Mike Marks (CFO)

Well, you know, resiliency is just part of our core operations. And so that's the way we think about, you know, resiliency is just part of the work we do every day in managing the company.

0:22:45

When I think about core growth in third quarter, we were pleased with core growth in third quarter, and, you know, call it a 10 % core growth increase. I think that reflect good volume growth. It reflected a good net revenue per unit improvement in the quarter and really good cost management as well. And I think as you see how we kind of set the guidance range in the upper half of the range, that gives you an implication of how we're thinking about fourth quarter.

0:23:15

And then, you know, we'll give you kind of our thinking in more detail about 2027 when we get on our fourth quarter call. So that would be the way to think about core growth. We'll have to validate it for fourth quarter, but we were really pleased with third quarter. And you get a sense from the upper half of the range comment that we have confidence coming in.

0:23:38
Operator

Your next question comes from the line of Matthew Gilmer with KeyBank.

0:23:43

Matthew, your line is now open.

0:23:45
Matthew Gilmer (KeyBanc)

Hey, thanks for the question. And on the pricing topic, you called out an acceleration in insured revenue per equivalent emissions. It sounded like that was better than expected. Can you talk about some of the drivers of that acceleration?

0:24:00
Mike Marks (CFO)

Sure. So Matthew, if I look at kind of net revenue per unit and I think about the insured book, obviously, you know, excluding the exchanges, the payer mix is still the big negative that we're dealing with in terms of net revenue per unit prior year number one is really the strength of our commercial volume our commercial excluding exchanges volume was up 2.7 percent over prior year quarter and that's strong and so that component of

0:24:29

our payer mix is definitely a part of why our net revenue per unit was a bit stronger in third quarter than the first half of the year the second we continue to see solid rate growth across our period of payer categories and then really third you know Paralon we see continued strengthening and their abilities to to collect our net revenues and yield our contracts their work to continue to strengthen our abilities to deal with the knowledge and underpayments continues to improve and so I think you know overall we had a good you know net revenue per unit of performance in the third quarter, especially kind of given the headwinds from our payer mix impacts.

0:25:14
Operator

Your next question comes from the line of Sam Dodge with BMO Capital Markets. Sean, your line is now open.

0:25:21
Sam Dodge (BMO Capital Markets)

Yeah, thanks. Good morning. Maybe just on the 2026 guidance, Mike, you said you're now pointing to the upper half of the range. I think that still implies core growth in Q4 will accelerate some from Q3. Maybe if you could just walk us through the visibility you have and what's going to drive that. Is that just incremental gains from resiliency you're expecting to come through?

0:25:45

And Sam, you also mentioned volume growth in Q3 broadly improved from the first half of the year. Is that part of the assumption too, that volumes also continue to improve into Q4?

0:25:55
Mike Marks (CFO)

Well, first I would say, I mean, I think if you look at the upper half of our guidance ranges that largely implies the core growth fairly consistent in fourth quarter third quarter would be the first thing out of the context and then i think the drivers are similar you know number one is we did see strength in volume in third quarter and and so that's encouraging for sure we've already mentioned a little bit on the net revenue for unit size there there tends to be a step up

0:26:23

from third quarter to fourth quarter in normal course and so we expect that normal seasonal trend to apply broadly. And then we do believe, as even Sam mentioned, not only in his opening, but as we were talking about in the first question, that our performance around our resiliency plan, our ability to manage costs, we continue to see strength across our resiliency plan in third quarter, in fourth quarter, and into 27, 28, and beyond. So I think those are the key components, Sean, that are kind of making up our guidance comment for fourth quarter of 2026.

0:27:05
Operator

Your next question comes from the line of Witt Mayo with Lee Rink. Witt, your line is now open.

0:27:13
Witt Mayo (Lee Rink)

Yeah, thanks. Did the Hicks headwind get larger in any particular market and any comments around AR collectability, balance after collectability would be helpful in any of the $400 million? Is that related to prior quarters? Thanks.

0:27:28
Mike Marks (CFO)

Well, I would say with it that our Hicks results in third floor were a little bit higher than we estimated. You know, we would have estimated, based on our guidance that we gave the second quarter, the third quarter would be, you know, 15, 16 % decline.

0:27:48

We ended up at about 19 % decline, which, you know, just reflects the sustained decline in our exchange volume. I like to put that in context, though. I mean, you know, that two or three points is about 2,000 adjusted emissions. You know, we have about a million adjusted emissions in the quarter. So, you know, these aren't perfect estimates, but it gives you a sense of kind of the numbers we're looking at here. You know, our experience in third quarter, and I mentioned this in my comments number one, you know, third quarter of last year was our high water mark.

0:28:22

So there was a bit of a prior year comparison difficulty. We did see, however, a sequential improvement in exchange volume from second quarter to third quarter, 26, of about 8%. And so all of that, when we brought it together, you know, it's kind of what guided us to say that we think for full year 26 now, you know, we'll be at to maybe slightly above the top end of our previously updated ranges for the exchanges. That's how, that's kind of how the numbers pulled through here in third quarter.

0:28:58
Operator

Your next question comes in the line of Ryan Langston with TD Cohen. Ryan, your line is now open.

0:29:08
Ryan Langston (TD Cowen)

Great, thanks. Appreciate the commentary on elective versus emergency surgical future trend growth. Can you maybe update us on what ASC versus HOPD surgical volume look like in the third quarter? Thanks.

0:29:24
Sam Hazen (CEO)

So the ASC surgery volumes were down 5.4 % on surgery. Overall case volumes were down about 3.7%. The primary pressure is related to the exchanges in our ASC book, very similar to the hospital side.

0:29:43

I would note, however, that even in light of the volume softness there, that our overall net revenue and earnings did show some growth to prior year. The hospital-based outpatient surgeries were down 2.9%. I think it's important to understand the construct of our ASC platform, and that informs at some level for us the macro forces that are out there with elective care at this particular juncture. And so when you sort through what's going on, yeah, there are certain issues in some centers that we have, but at sort of an aggregated level, it informs a little bit of our macro thinking around some of those forces that are influencing overall demand.

0:30:41
Operator

Your next question comes in the line of Sarah James with Cantor Fitzgerald. Sarah, your line is now open.

0:30:50
Sarah James (Cantor Fitzgerald)

I'd like to keep going on that topic. So is there a way to unpack how much of the inpatient and outpatient surgical trend pressure so far this year is exchange-related versus how much is affordability and things that may be continuing? And then given your comment on affordability pressure, are you assuming any stronger than normal tailwind in 4Q ahead of the deductible reset?

0:31:24
Sam Hazen (CEO)

We are not at this particular juncture assuming anything outside of normal seasonality, but your point is relevant. It could be that some folks are making decisions. We've seen that on the margins in other years, but at this particular point in time, we are not. But when I look at our elective care, surgical care, I mean, the HICS is a very large percentage of the explanation. It goes back to what we've been saying all of last year and all of this year.

0:31:59

Coverage for people matters. And it creates access, affordability, and elective care. It's a very fundamental element to individuals' abilities to get the health care they need. And so it's a large piece of the elective equation is the coverage dynamic that's occurred in the Hicks environment. And I don't have an exact percentage here in front of you, but it's a very significant piece of the variance. And we've called that out. and we think that has some incremental effects in other payer classifications as well as we talk about the affordability more broadly.

0:32:44
Operator

Thank you. Your next question comes from the line of Justin Lake with Wolf Research. Justin, your line is now open.

0:32:53
Justin Lake (Wolfe Research)

Thanks. Good morning. A couple quick number follow-ups. First on 2027 DPP, appreciate the 550 to 650 number. I was hoping you can isolate your estimate here of how much of that number comes from the Q4 DPP cut as HR1 gets implemented versus the 2026 at a period that doesn't reoccur. And then on the exchange impact for Q4, can you tell us how much your guidance assumes that that sequential exchange volume growth occurs from Q3 to Q4 this year?

0:33:28

I know you just gave us the Q2 to Q3 number.

0:33:33
Mike Marks (CFO)

Sure, it's on Q3 to Q4. Well, let me start with the first part of your question. So, as Sam noted in his comment, we expect to receive approximately $550 to $650 million less in Medicaid state sepulchral payment net benefit in, you know, in 27 versus 26. And that's because of the grandfather approvals that happened in 26 that were really related to prior years. The predominance of that, Justin, was related to Florida, which we previously disclosed.

0:34:09

You know, the rest is really related to the other grandfather states like Virginia, Georgia, et cetera. So, you know, that's really the makeup of those kind of the out of period state supplemental payment programs. If I think about what the guidance implies over the fourth quarter, you know, we are finishing September 26th year to date with $650 million of incremental net benefit from states of open payments. So if you think about the full year guidance range that we just updated to $600 to $800 million, that would give you a sense for what we're thinking about fourth quarter.

0:34:47

You know, at midpoint, it would be another $50 million net incremental benefit, and then you can see the range. And so that's kind of how we're thinking about that for fourth quarter. And then on exchanges, not ready to quote a sequential move from Q3 to Q4 at this point. I would note, and we noted this on our second quarter call, you know, I would point you back to fourth quarter of 25, where we did see a slowdown occur in our exchange volumes from, you know, from Q3 to Q4 last year.

0:35:19

And so we do think there is a bit of a benefit comparison benefit in fourth quarter of 26, given that factor.

0:35:29
Operator

Your next question comes from the line of Kevin Fishbeck with Bank of America. Kevin, your line is now open.

0:35:37
Kevin Fishbeck (Bank of America)

Great, thanks. I just, a lot of moving pieces here. I just want to make sure I understand the new guidance versus the old guidance. Is the right way to think about it that the new guidance includes about $300 million more of SDPs and 100-plus million more of headwinds from payer mix, and then that combination is largely the increase in guidance from the prior?

0:36:06

Is that the right way to think about it? And then just a clarification on the HICS headwind that you guys are talking about. Is it purely just an uninsured number? people coming in and not paying, or are you also kind of thinking about the implication of lost surgery from people losing HICS coverage in that number? Thanks.

0:36:26
Mike Marks (CFO)

Well, let's walk to guidance first, Kevin. So, yes, I mean, from supplemental payments, we've raised our net benefit guidance by about $300 million.

0:36:35

So that's certainly a piece of it. If you think about the exchanges, you know, With this idea of kind of app or slightly above the top end of our previously released estimates, you're in the $100 to $200 million increase in headwinds related to that. And then the third thing I would call out is just core growth. I think, as we noted on today's call, we believe our fourth quarter core growth should be good. But the net of those three factors really led us to making the comment that we believe will be in the upper end of our guidance ranges for the full year, which will give you a sense of how all that comes together.

0:37:17

So that would be the walk down on guidance.

0:37:21
Operator

Your next question comes from the line of Scott Fidel with Goldman Sachs. Scott, your line is now open.

0:37:30
Scott Fidel (Goldman Sachs)

Hi, thanks. Good morning. The question is just first on the, I know there's been some questions around it on the third quarter and next year, but on the fourth quarter, just maybe the visibility and expectations that you have around elective procedures and sort of how scheduling seems to be playing out in terms of just normal seasonality.

0:37:58

And then And I just wanted to also ask in terms of the headwinds that you've laid out for next year relating to OB-3, whether there's anything specifically relating just to the CMS policy that now is requiring all the 1115 waivers to be budget neutral from a federal perspective and just whether your intel from the states, are you seeing any change in sort of approach or in terms of applications or, you know, sort of anything that you think could be sort of play out, you know, relating to that policy that could impact fundamentals in 27.

0:38:35

Thanks.

0:38:35
Mike Marks (CFO)

On elective, Scott, and I think Sam mentioned this when he was answering the previous question of surgery. At this point, we did not assume any pickup on elective demand related to copays and deductibles in the fourth quarter. I think we expect a normal seasonal move from Q3 to Q4, but we did not build into our guidance thinking some kind of improvement or pull forward of demand from an elective standpoint in the fourth quarter. When I think about HR1 for 2027, and we continue to monitor all the rulemaking, we know that our states continue to follow their applications and feel good about the processes that we see in flight.

0:39:23

I would mention on HR1 that, you know, the big changes really work requirements for able-bodied adults in our expansion states. You know, I might mention just for context that expansion states are 40 % of our Medicaid volumes and revenues. And when you think about work requirements targeting able-bodied adults in those expansion states, you know, when you take out the seniors and the disabled and the kids and those that are medically frail, we think that work requirements would be, you know, kind of applicable to about 15 % to 20 % of our Medicaid volume.

0:39:58

And so, you know, the net of all of that, while we're not quite ready to size it in terms of earnings impact, we do think that work requirements specifically would have a bit of a modest impact in full year 27. So, that's the main things we're watching for HR1 next year, and I think that wraps both of your questions.

0:40:20
Operator

Your next question comes from the line of Stephen Baxter with Wells Fargo. Stephen, your line is now open.

0:40:29
Stephen Baxter (Wells Fargo)

Hi, thanks. Just a couple of follow-ups on the breakout of adjusted admissions. I think you gave us the commercial exchange number already, but could we get the Medicare, your year-over-year AA growth, Medicaid, and then I guess you gave us the exchanges on a quarter-over-quarter basis. If you also had the year-over-year basis, that would be helpful, too. Thanks.

0:40:50
Mike Marks (CFO)

Sure. So these are same facility adjusted admissions compared to prior year for third quarter.

0:40:56

Medicare is up 3.2%. Medicaid is up 2.7%. Commercial excluding the exchanges are up 2.7%. And then the exchanges are down 19 % to the primary quarter. As I noted in my commentary though, that is an 8 % sequential improvement from Q2 to Q3.

0:41:19
Operator

Our next question comes from the line of Jason Casorla with Guggenheim Securities. Jason, your line is now open.

0:41:28
Jason Casorla (Guggenheim Securities)

Great, thanks. Good morning. I wanted to turn back to the volume discussion.

0:41:36

You know, you guys have seen pretty solid volume acceleration over the past couple of quarters. That clearly stands out. You're talking about 2 % to 3%. Volume growth next year. I was just hoping if you can give us a little more in terms of what you're attributing the volume strength to. I mean, you've talked to the solid demand environment, but can you help quantify maybe like how much you're thinking is coming from the benefits of in-market initiatives, all the work you've done to expand capacity and the like, and how that kind of fits into that two to 3% mold that you're looking forward for next year would be helpful.

0:42:08

Thanks.

0:42:08
Sam Hazen (CEO)

So if you start at the top here, I mean, it's our belief that there's sort of inherent demand growth in the markets that we serve, coming from population growth, aging baby boomers, chronic conditions, new technology even. All of this sort of converges to create an upward movement in demand in the markets that we serve. And so that's a starting point. We do think across a lot of our markets, we're gaining market share incrementally. We do have some markets that we have to adjust to different dynamics and respond at that level.

0:42:51

But when you look at it in the main, over time, we picked up market share. Our approach to our networks is continuing to advance with respect to our ambulatory platform. We're up to almost 3,000 units through acquisition of urgent care, ambulatory surgery centers, and other outpatient facilities that complement our hospital's ecosystem and create for our patients a more convenient and accessible location and efficient service. That continues to evolve in our networks, and as we mature on that platform and leverage the restructuring that we did with one of our group presidents, Charles Gressley, I anticipate that we're going to be able to move our ambulatory platform forward and create even more growth out of it.

0:43:48

Again, meeting our customers, our patients, where they live so that we can create convenience A second important initiative for us is creating patient coordination once they do hit one of our ambulatory facilities. And through patient coordination, we think we can create a better experience for the patient and ultimately integrate them into our system. And if, in fact, they need acute care services, we're helping them achieve that in an efficient and transparent way. So that's evolving also.

0:44:26

Clearly, we're investing in our hospitals with capital. We are adding beds. We're adding other capacity within our facilities to manage the demand. We're running the company at an all-time high when it comes to occupancy levels, pushing 75 % on our inpatient platform. We're benefiting, however, through patient flow initiatives where we're able to improve the flow for our patients and get them to the care sites they need. That's creating capacity for us as we evolve also.

0:45:00

So all of these things combined are yielding growth for our company. And then lastly, it's how we engage with our physicians and support our physicians with their practices, meet them where they are, and find ways to invest in clinical capabilities, be very effective and efficient in how we process their patients, and then ultimately give them a voice in what's going on. That's allowing us to respond largely to our physician requirements as well. So all of those things, it's impossible to point to one thing.

0:45:35

And each market's slightly different. We have to nuance our approach in each market to address those differences. That's why we're organized as we are with our divisions. But I think with 22 consecutive quarters of growth in volume, which is quite impressive from my standpoint, and then with the return on capital, and then with the improvements in quality and service for our patients we feel like our model works and gives us again the staying power that I mentioned in my comments and allows us to push into the future with confidence and a belief that we can achieve our objectives.

0:46:20
Operator

Your next question comes from the line of Raj Kumar with Stevens. Raj your line is now open.

0:46:27
Raj Kumar (Stevens)

Maybe on the pricing conversation, just curious on, I know you're mostly contracting on the commercial side for 2027, but you kind of think about 2028 or payers starting to, you know, embed any explicit assumptions around, you know, coding and more accuracy on that front. And just curious across, you know, one of that node and in terms of how diffuse it is across the platform, or is it still in early stages around kind of the coding on that front?

0:47:01
Sam Hazen (CEO)

You know, this is Sam. Let me lift up a little bit on this point. It's important for us to have solid relationships with the major payers in our community, and we do that. And we're able to meet our objectives and meet our objectives in most circumstances. And that's been, I think, part of our ability to execute our strategy and help them execute their strategy. Our contracting process is transparent with our major payers, and we are accomplishing contract cycling that naturally occurs over time.

0:47:45

We're deep into 2027, and we're not as deep into 2028, but we are making progress on 2028 as contracts mature and move into the cycle that naturally occurs. We're able to achieve our objectives and then support the objectives of the major payers. Our teams are working very earnestly to come up with solutions for people. And what I mean by that is the patient, the providers, and the beneficiaries that are all connected to what we do administratively between the insurance companies and the hospitals.

0:48:27

HCA and many of the major payers are working diligently to eliminate the friction, create a more cost-effective solution, and sort of reduce the administrative complexity that exists within the system. And I'm encouraged by the progress that we're making. I'm encouraged by the attitudes of many of the payers. And I think we're going to progress over the next year or so and really create value for our patients and for the beneficiaries in a manner that starts to change the paradigm a little bit between what's going on with payers and what's going on with HCA.

0:49:07

So more to come on that, but we are in fact progressing on just about every front with respect to our major payers.

0:49:17
Operator

Your next question comes from the line of Benjamin Rossi with J .P. Morgan. Benjamin, your line is now open.

0:49:25
Benjamin Rossi (J.P. Morgan)

Hey, good morning. Thanks for the question. Following up on your market-specific commentary, with some of the broader operational pressures you're facing, I appreciate that you're still adding inpatient capacity and outpatient density. But as you assess your options, are you at all considering any market exits or potential changes to your footprint?

0:49:49

Or with these pressures hitting everyone, do you consider yourself a potential buyer as competitors similarly face these headwinds? I guess just curious where you stand in market positioning at this time, sir. Thanks.

0:50:02
Sam Hazen (CEO)

So we compete in 43 markets roughly in the U .S. Some of them are smaller and they get counted in that. And then some are mega markets. And over the last seven, eight years, we have been fairly intentional about looking at our individual markets and determining whether or not we can execute our model and be successful and meet the needs of our constituents.

0:50:30

And we've largely pruned the portfolio of HCA down to the markets that we think can go the distance. And today, the markets that we have are ones that we're investing in at different levels, as you would expect, because of the different circumstances from one market to the other, the different opportunities that exist. So I don't see any significant change to our market configuration at this particular point, because we've been intentional over the past few years to optimize the portfolio, if you will, and put ourselves in a position where we can succeed and build out the model that we think adds value to our patients and adds value to the organization as a whole.

0:51:18

That allows us to focus our capital spending, to focus our talent and our resources on a smaller footprint, but with a very significant growth prospect, we believe, for the company. So that's where we are. We always have one or two items here or there. With regard to new markets, you're right, we're built to be bigger. We know that, but we just haven't seen a lot of opportunities yet. If opportunities do develop, as usual, we'll be opportunistic and take a look at whether or not it's affordable, whether or not we can execute our model, and make the right decision at that particular juncture.

0:52:06

We do have a lot of outpatient activity, as I mentioned earlier, that is important to building out the network overall so that it is accessible for our patients, and we continue to invest in those opportunities as they develop as well.

0:52:23
Operator

Your next question comes from the line of Andrew Mock with Barclays. Andrew, your line is now open.

0:52:31
Andrew Mock (Barclays)

Hi, good morning. Can you talk about what you're seeing in the market as it relates to the removal of the inpatient-only list, both in terms of procedure migration today and actions taken now in anticipation of future migration?

0:52:47

And how should we think about the impact of the inpatient-only list and potential outpatient capacity additions against the backdrop of fixed surgeons? Thanks.

0:52:56
Mike Marks (CFO)

Andrew, if I think about the inpatient-only list, obviously we're in year one of three-year phase out this first year is focused a bit more on ortho and musculoskeletal type procedures so that's what we're seeing i think if i look at our elected book i would say you know after the exchanges which were the biggest driver of elective surgical volume weakness the second driver would have been medicaric and especially on the inpatient side so we are seeing some some impact of the inpatient only list.

0:53:31

I think it's fair to say that the outpatient market for surgery is a bit larger than the inpatient market for surgery. There's more competitors, and so that's a factor. When I think broadly, though, we look at ambulatory surgery centers, as Sam just walked through, as part of our networks. And building out our ambulatory networks, they play an important role. We are continuing to invest in our operating rooms and our surgical platforms in the inpatient side and the hospital side for outpatient surgery and in our ASC platforms and believe that it's a long-term important component.

0:54:08

I don't think that anything we're seeing would say that it would drive a material change in the way we're approaching building out our networks. And again, Mike, I think the fact that we have, you know, 25 different service categories that we focus on across the company that are different gives us an ability at times to invest, just like I said, in different markets. We can invest in different services depending on demand, forecasts, population trends, competitive dynamics, and so forth.

0:54:43

And you see that in our volume when it comes to some of the pressures we've seen on elective care. We've all set that with other services that give the networks a level of resiliency, give the demand sort of equation inside of the market support when it comes to our ability to provide patient care. And I'm not sure that is fully recognized in some of these isolated discussions about service A, service B. Clearly, there are always issues.

0:55:21

We've had issues with stuff migrating from inpatient to outpatient. We've had new, over the years, we've had new technologies evolve that change the procedure approach for physicians and better for the patients. Obviously, we embrace that, but we've been able to backfill with other services, expand our markets, get into new capabilities, and ultimately keep the company moving forward in the face of those incremental changes that occur. And that's what I think is unique in many respects to our platform, the services we provide, and how we approach our business.

0:56:03

And it gives us the diversification in some regards that allows us to navigate through these incremental issues that surface from time to time.

0:56:13
Operator

Your next question comes from the line of Craig Huttenbach with Morgan Stanley. Craig, your line is now open.

0:56:21
Craig Huttenbach (Morgan Stanley)

Yes, thank you. Mike, the comment that resiliency is part of the core now, can you just touch on some of the applications you've been able to accelerate this year, as well as any untapped opportunities you see on a longer-term basis on resiliency?

0:56:42
Mike Marks (CFO)

When we think about resiliency, you know, we largely think about four key focus areas that really make up this multi-faceted effort across the enterprise. The first one is really revenue integrity and working to ensure that we collect the revenue from the services we provide under the contracts that we operate. That's number one. Number two is asset optimization, Craig, and that's important. That's that patient flow that Sam was talking about. And certainly that's important on the inpatient side.

0:57:14

It's also important in our emergency rooms, our operating rooms, our cath labs. And so we continue to see good performance on patient flow. And there's a lot of opportunity ahead. We are nowhere near the back innings here on asset optimization and feel good about the work ahead there. Third is variable costs, things like labor, supplies, and even some of our variable operating costs, which are performing well this year. We have a number of resiliency plans that are driven to focus on variable costs.

0:57:49

And when we look ahead, we continue to see opportunity and the variability across the company in our benchmarking tools and advanced analytics and taking that forward. And then lastly are fixed costs, both at corporate and in the field, which are an important part here. So as I think about where we are today, we have good resiliency efforts that have been in our past and that are certainly improving our current year's performance. We have a great line of sight now going into 27 and into 28 and beyond.

0:58:22

And I think about things like the digital transformation as really being a key enabler that gives us that confidence that we're going to have resiliency benefits in the years to follow. We continue to build out our global capabilities. I think about the underlying work of expanding our shared service platforms. We have a number of expansions in flight where, for example, Paralon is taking on additional administrative functions for the company and bringing shared service scale and expertise to broader parts of our work.

0:58:56

So as I sit here today at the end of third quarter of 26, we believe that we're in a really good spot. We have a multi-year, multi-faceted enterprise-wide approach to resiliency and we believe it's going to produce great results as we move forward.

0:59:10
Frank Morgan (Investor Relations)

Christine, I think we're at the end of our allotted time for questions.

0:59:14
Operator

We have reached the end of the Q &A session. I will now turn the call back to Frank for closing remarks.

0:59:23
Frank Morgan (Investor Relations)

Christine, thank you for your help today on the call and thanks to everyone for joining us. Please reach out to me if you have any additional questions.

0:59:31
Operator

Thank you very much. This concludes today's call. Thank you for attending. You may now disconnect.